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Purpose: The purpose of this study was to evaluate the effect of optimally timed combination 
treatment with angiogenic and glycolytic inhibitors on tumor burden, hypoxia, and angiogenesis 
in advanced retinoblastoma tumors.
Methods: LHBETATAG mice (n = 30) were evaluated. Mice were divided into 5 groups (n = 6) and 
received injections at 16 weeks of age (advanced tumors) with a) saline, b) anecortave acetate 
(AA), c) 2-deoxyglucose (2-DG), d) AA + 2-DG (1 day post-AA treatment), or e) AA + 2-DG 
(1 week post-AA treatment). Eyes were enucleated at 21 weeks and tumor sections were ana-
lyzed for hypoxia, angiogenesis, and tumor burden.
Results: Eyes treated with 2-DG 1 day post-AA injection showed a 23% (P = 0.03) reduction 
in tumor burden compared with 2-DG alone and a 61% (P , 0.001) reduction compared with 
saline-treated eyes. Eyes treated with 2-DG 1 week post-AA injection showed no significant 
decrease in tumor burden compared with 2-DG alone (P = 0.21) and a 56% (P , 0.001) decrease 
in comparison with saline-treated eyes. 2-DG significantly reduced the total density of new 
blood vessels in tumors by 44% compared to saline controls (P , 0.001), but did not affect the 
density of mature vasculature.
Conclusions: Combination therapy with angiogenic and glycolytic inhibitors significantly 
enhanced tumor control. Synergistic effects were shown to be dependent on the temporal 
course of treatment, emphasizing optimal timing. 2-DG was shown to reduce the density of 
neovessels, demonstrating an antiangiogenic effect in vivo. As a result, angiogenic and gly-
colytic inhibitors may have significant potential as alternative therapies for treating children 
with retinoblastoma.
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Introduction
Retinoblastoma is the most common intraocular malignancy in children, affecting ∼1 
in 15,000 children, for an incidence of 250–300 new diagnoses a year in the United 
States.1–4 Treatment has evolved, with survival rates climbing to 99%, and a large 
percentage of children maintaining functional vision.5 Current treatment includes 
chemoreduction (carboplatin, vincristine, and etoposide) with local consolidation 
(thermotherapy or cryotherapy). Success rates are reported as 100% for small tumors, 
decreasing to 47%–83% for tumors with diffuse vitreous or subretinal seeds.6,7 
Options for tumors that fail therapy include additional chemotherapy with associated Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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systemic toxicities,8–15 radiation with the risk of secondary 
malignancies,16,17 and ultimately enucleation.8 As a result 
of the poor response of advanced retinoblastoma tumors to 
current therapy and the inherent toxicities of current che-
motherapeutics, development of local adjuvant therapies is 
imperative.
A paradigm shift in cancer treatment has recently 
occurred as therapies target not only hyperproliferating 
tumor cells with chemotherapy, but also target the tumor 
microenvironment.18,19 Hypoxia has gained considerable 
attention, being correlated with tumor growth, progression, 
resistance, and metastasis.20 Solid tumors are known to 
consist of hypoxic regions, a microenvironment consist-
ing of slow-growing, malignant cells that prove resistant 
to chemotherapy and radiation.21–23 Under harsh, hypoxic 
conditions, tumor cells adapt and survive through control 
of gene expression, leading to altered cellular metabolism 
and angiogenesis.24 Slowly proliferating cells in the hypoxic 
regions must rely on anaerobic glycolysis to utilize glucose 
for energy in the form of ATP. Our previous study was the 
first to show that regional hypoxia is present in advanced 
tumors of a transgenic retinoblastoma model, with hypoxia 
ranging between 20% and 26%. It was also shown that 
systemic administration of 2-deoxyglucose (2-DG) alone as 
well as combined with chemotherapy significantly decreased 
tumor hypoxia and tumor burden.25
Angiogenesis has also been identified as a critical 
component of tumor growth and survival. As solid tumors 
proliferate, they are dependent on the development of a net-
work of new vasculature to deliver blood and oxygen to the 
highly metabolic neoplastic cells. Angiogenesis consists of 
a complex and coordinated process that involves the devel-
opment of new blood vessels from existing ones. Multiple 
stages of angiogenesis can be targeted with antiangiogenic 
agents, making blood vessels an attractive target in cancer 
therapy. We have shown that the vasculature in retinoblastoma 
tumors is heterogeneous, consisting of mature and immature 
neovessels, with proportions changing as more advanced 
tumors contain mature vessels. Vascular targeting therapies 
with angiogenic inhibitors alone or in combination with 
chemotherapeutic agents have been shown to effectively 
control tumor burden in the LHBETATAG mouse model for 
retinoblastoma.26  In addition, our group has also shown that 
2-DG effectively inhibits endothelial cell angiogenesis in 
vitro and in vivo.27
The purpose of the present study was to evaluate the 
efficacy and demonstrate the importance of optimally 
timed combination therapy with angiogenic and glycolytic 
inhibitors in controlling advanced tumor burden and reduc-
ing intratumoral hypoxia in the LHBETATAG mouse model for 
retinoblastoma. Additionally, we evaluated the effect of 2-DG 
on angiogenesis in vivo.
Methods
LHBeTATAg transgenic mice
The study protocol was approved by the University of 
Miami Institutional Animal Care and Use Committee. All 
experiments were conducted in accordance with the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision 
Research. The LHBETATAG transgenic mouse model used in 
this study has been characterized previously.28
injections
LHBETATAG transgenic retinoblastoma mice were evalu-
ated (n = 30). The mice were divided into 5 groups at 16 
weeks of age and received injections of either saline (APP 
  Pharmaceuticals, Schaumburg, IL), anecortave acetate (AA; 
300 µg/20 µL; Alcon Pharmaceuticals, Fort Worth, TX), 2-DG 
(500 mg/kg; Sigma-Aldrich, St Louis, MO), AA and 2-DG 
(1 day post-AA injection), or AA and 2-DG (1 week post-AA 
injection). AA was administered through a single subconjuncti-
val injection to the right eyes only, and did not demonstrate any 
significant deleterious ocular side effects that are associated 
with ocular glucocorticoid therapy.26 2-DG was administered 
through intraperitoneal injection, 3 times a week for 5 weeks. 
Saline (20 µL) was administered through subconjunctival 
injections. Eyes were enucleated at 21 weeks of age and were 
assessed for hypoxia, tumor burden, and angiogenesis.
Tumor burden measurements
Eyes were enucleated, snap frozen, serially sectioned, 
and processed for standard hematoxylin and eosin (H&E) 
  staining. Microscopic images of H&E-stained sections 
(50 8 µm sections/eye) were obtained with a digital camera 
at a magnification of ×40. The section of the eye containing 
the largest cross-sectional tumor area was chosen for analysis. 
Tumor boundaries were traced (Image Pro Express Software; 
Media Cybernetics, Silver Spring, MD). Tumor areas for all 
eyes were averaged, yielding an average area for each group. 
Tumor burden was expressed as the tumor/globe ratio by 
dividing the tumor area by the area of the globe to normalize 
the data as previously described.26
Measuring hypoxic regions
To assess tumor hypoxia after treatment, LHBETATAG 
mice 21 weeks of age (n = 6 per group) were injected Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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intraperitoneally with a 0.16 mL suspension of pimonidazole 
(a drug used to detect hypoxia that penetrates all tissues, 
including the brain). This suspension consisted of 10 mg 
of pimonidazole hydrochloride (Chemicon, Temecula, CA) 
in 1 mL saline. Pimonidazole is known to bind to thiol-
containing proteins in cells under low oxygen tension.29 
These adducts can be detected with specific antibodies and 
stained using immunohistochemical techniques. Animals 
were euthanized 2 h after pimonidazole injection, and eyes 
were harvested and sectioned for histopathologic examina-
tion. Eyes were fixed with cold methanol for 10 min and 
immunostained with a directly labeled antibody recogniz-
ing pimonidazole adducts (Hypoxyprobe 1-Mab-1-FITC, 
clone 4.3.11.3; Chemicon) or the same concentration of a 
directly labeled isotype control antibody (mouse IgG1-FITC; 
Caltag, Burlingame, CA). Background signal intensities were 
minimal. All samples were normalized to intensities from 
isotype controls. The values reported indicate the percentage 
of pimonidazole-stained areas in the tumors.
Serial cross sections of eyes were examined for the 
presence of the described markers with a laser confocal 
microscope (TCP SP5; Leica Microsystems, CMS GmbH, 
Mannheim, Germany). All images were digitally acquired 
and recompiled (Photoshop CS; Adobe, San Jose, CA). 
  Sections were viewed at ×200 magnification.
Blood vessel measurements
2-DG (500 mg/kg) was administered through intraperitoneal 
injection into LHBETATAG retinoblastoma tumor-bearing mice 
starting at 16 weeks of age, 3 times a week for 5 weeks (n = 5). 
Saline was administered using the same method (n = 4). Mice 
were euthanized at 21 weeks of age. Tumor samples were 
frozen in OCT immediately after enucleation and serially 
sectioned (8 µm). Slides were fixed with methanol for 10 min 
(-20°C) and immunohistochemical analyses were performed. 
Total vessels were detected with Alexa Fluor 568 conjugated 
lectin (Bandeira simplicifolia, a pan-endothelial binding 
agent; 1:1000; Invitrogen, Carlsbad, CA).30 Mature vessels 
were detected with α-smooth muscle actin (α-sma) Cy3 
conjugate (1:3000; Sigma-Aldrich), which specifically binds 
to pericytes.31 Neovessels were detected with anti-endoglin 
(CD105 Wi, 1:500; Abcam, Cambridge, MA), which has been 
shown to have specificity for endothelial cells (ECs) under-
going angiogenesis.32 Alexa Fluor 568 goat anti-mouse and 
488 donkey anti-mouse were used as secondary antibodies 
for anti-collagen type IV and endoglin, respectively (1:500; 
Invitrogen). Omission of the primary antibody (secondary 
only) was used as a negative control for nonspecific binding. 
Cell nuclei were stained for 5 min with 4′,6′ diamidino-2-
phenylindole (DAPI, 1:5000; Invitrogen).
Analyses were performed on digitized fluorescence 
microscopic images (×200) using Adobe Photoshop 
  (Photoshop CS; Adobe). Tumors were analyzed for vascular 
hotspots (four or five hotspots per tumor sample, depending 
on the tumor size). Areas of each marker within a hotspot 
were measured and given as a fraction of the magnification 
field.
These densities were averaged for each marker within 
each tumor.
statistical methods
Pimonidazole fluorescence in tumors and tumor burden 
analyses were investigated with two-way analysis of vari-
ance (ANOVA). Post hoc least-significant different tests 
were used to evaluate differences between treatment groups. 
Tumor burden differences between groups were evaluated 
by two-sample t-test. Differences in means among three or 
more groups were analyzed by ANOVA. Two-sided, two-
sample t-tests were used to compare levels of new and mature 
blood vessels between controls and animals receiving 2-DG 
treatment. Means in between two groups were compared 
by t-test analysis. Differences were considered statistically 
significant at P , 0.05. Data are presented as means and 
standard deviation.
Results
Tumor burden
Tumor burden was analyzed for all groups (Figures 1 and 2). 
In the AA-treated group (Figure 2B), there was no change 
in tumor area in comparison with the saline-treated group 
(P = 0.43) (Figure 2A). There was a significant decrease in 
tumor burden (61%) following combination treatment with 
2-DG administered 1 day post-AA treatment (Figure 2D) in 
comparison with the saline-treated group (P , 0.001) and a 
59% decrease in tumor burden in comparison with the AA-
treated group (P , 0.001). Notably, there was a 23% decrease 
in tumor burden in comparison with the eyes treated with 
2-DG alone (P = 0.03) (Figure 2C). There was a significant 
decrease in tumor burden (56%) following combination treat-
ment with 2-DG administered 1 week post-AA (Figure 2E) in 
comparison with the saline-treated group (P , 0.001), and a 
54% decrease in tumor burden in comparison with the AA-
treated group (P , 0.001). In contrast to 2-DG administered 
1 day post-AA, 2-DG given 1 week post-AA showed no 
significant decrease in tumor burden in comparison with the 
eyes treated with 2-DG alone (P = 0.21). Finally, there was Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
132
Houston et al
*
*
0
0.5
1
1.5
2
2.5
3
3.5
T
u
m
o
r
 
B
u
r
d
e
n
 
(
m
m
2
)
Treatment
Saline 2-DG 2-DG 1-week
post-AA
2-DG 1-day post-
AA
Figure 1 Tumor area in anecortave acetate (AA) and 2-deoxyglucose (2-Dg) groups in LHBeTATAg retinal tumors. LHBeTATAg mice 16 weeks of age (advanced tumors) were 
treated with saline, AA (300 µg/20 µL), 2-Dg (500 mg/kg), AA (300 µg/20 µL) + 2-Dg (500 mg/kg 1 day post-AA injection), or AA (300 µg/20 µL) + 2-Dg (1 week post-AA 
injection). Eyes were analyzed 5 weeks post-initial treatment for residual tumor burden. There was a significant reduction in tumor area with 2-DG alone, as well as after 
combination treatment with AA and 2-Dg compared to the saline control group (P , 0.001). notably, there was a significant difference in tumor burden (23% reduction) 
between groups treated with 2-Dg 1 day post-AA compared to 2-Dg alone (P = 0.03).
Notes: *statistically significant difference (P < 0.05).
no significant difference in tumor burden between the two 
combination treatment groups (2-DG + AA) (P = 0.31).
Percent hypoxia
LHBETATAG retinal tumors treated with saline were used as 
controls and were analyzed for hypoxic regions   (Figures 3 and 
4A). The tumors were found to be 19% hypoxic (P , 0.001). 
In the AA-treated group, 18% of the tumor was hypoxic 
(P , 0.001) (Figure 4B). In the group treated with 2-DG 1 day 
post-AA injection, the tumor was 0.24% hypoxic (P , 0.001) 
(Figure 4D). In the group treated with 2-DG 1 week post-AA 
acetate injection, the tumor was 0.3% hypoxic (P , 0.001) 
(Figure 4E). There was no significant change in hypoxic area 
in the AA-treated group in comparison with the saline-treated 
group (P = 0.19). There was a significant decrease (98%) in 
hypoxia in the groups treated with 2-DG 1 day and 1 week 
post-AA injection in comparison with AA alone (P , 0.001 
for both groups). There was no significant difference in 
hypoxic areas between the groups treated with 2-DG 1 day 
and 1 week post-AA injection in comparison with the 2-DG-
treated group (P = 0.98 and P = 0.95, respectively). There 
was no significant difference in hypoxic areas between the 
two groups treated with combination treatment (AA + 2-DG) 
and 2-DG therapy (P = 0.93) (Figure 3).
effect of 2-Dg on tumor vasculature
To assess the effects of the administration of 2-DG on the 
vasculature of LHBETATAG retinal tumors, the densities of 
new, mature, and total blood were measured (Figure 5). 
In advanced disease (21 weeks of age), a significant reduction 
(44%) in the average density of new blood vessels (endoglin) 
was found in the retinal tumors that received 2-DG treat-
ment when compared with controls (P , 0.001, ANOVA). 
However, there was no significant difference in the average 
densities of both mature (α-sma) and total vasculature (  lectin) 
in the retinal tumors that received 2-DG treatment when 
compared with controls (P . 0.05, ANOVA).
Discussion
Our current study is the first to demonstrate the com-
bined treatment of advanced retinoblastoma tumors in the 
LHBETATAG mouse model with angiogenic inhibitors and gly-
colytic inhibitors avoiding chemotherapy. We have previously 
demonstrated the effectiveness of 2-DG alone in decreasing Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
133
Optimally timed combination therapy
tumor hypoxia and in tumor control. However, when 2-DG 
was combined with the angiogenic inhibitor, AA, advanced 
tumor control was significantly increased, as the combined 
treatment resulted in a 23% decrease in tumor burden com-
pared to 2-DG alone. Importantly, the enhanced response of 
tumors to the combination treatment occurred in the group that 
received 2-DG 1 day after AA treatment, whereas the group 
treated 1 week after AA did not differ significantly from 2-DG 
alone. Mice were treated at 16 weeks of age, when eyes harbor 
advanced tumors. As shown in prior studies, these advanced 
tumors consist of heterogeneous vasculature, with a greater 
proportion of mature versus immature vessels. As a result, 
AA would be expected to have a more robust effect the earlier 
tumors were treated, as these earlier tumors have a greater 
proportion of immature vessels. Moreover, advanced tumors 
have a greater degree of hypoxia, thus maximizing the effect 
of 2-DG treatment, and potentially diminishing the observed 
effect of the AA. Despite these limitations, combination 
treatment with AA and 2-DG proved to significantly enhance 
tumor control compared to 2-DG alone.
Solid tumors are known to consist of hypoxic regions 
composed of slow-growing, malignant populations of tumor 
cells. The cells in the hypoxic microenvironment must adapt 
to these harsh conditions in order to survive. Adaptations 
may be mediated through a variety of mechanisms, with 
cells altering the genetic expression of certain key path-
ways. Several O2-sensitive pathways have been identified, 
including the mammalian target of rapamycin (mTOR), 
hypoxia-inducible factor (HIF), unfolded protein response 
(UPR), and the urokinase plasminogen activator (uPA) sys-
tems, that potentially contribute to adaptation and survival.24 
Reduced oxygen tensions have been shown to upregulate 
the transcription factor HIF, leading to increased produc-
tion of genes for glucose transporters (GLUT), glycolytic 
enzymes, and angiogenesis.33–35 Additionally, the uPA system 
may activate enzymes, notably gelatinases such as matrix 
metalloproteinases (MMP) that break down the extracellular 
matrix, facilitating angiogenesis and tumor invasion.36 As a 
result, adjuvant therapies that target key aspects of these 
adaptations are needed.
Glycolytic inhibitors, such as 2-DG, exploit the altered 
cellular metabolism that hypoxic cells utilize for survival. 
Unlike cells in normoxic conditions, the cells in the hypoxic 
regions must use anaerobic glycolysis as the sole source of 
energy. 2-DG competes with glucose for cellular transporters 
(ie, GLUT-1) and key glycolytic enzymes, such as hexoki-
nase. As a result, 2-DG inhibits the metabolic machinery of 
the cells, preventing the production of energy in the form 
of ATP, and effectively causing cell death. Our previous 
studies have demonstrated that targeting hypoxic cells with 
2-DG alone, as well as combining this treatment with che-
motherapy, leads to a significant reduction in tumor hypoxia 
and tumor burden.25
2-DG has been shown to be effective at targeting hypoxic 
cells, as well as inhibiting endothelial cell angiogenesis.27  
The spatial distribution of blood vessels and the effects of 
antiangiogenic agents in LHBETATAG retinal tumors have been 
characterized previously.37 In the current study, we have shown 
that 2-DG significantly reduces the density of immature 
neovessels by 43% compared to controls. Conversely, 2-DG 
does not have an effect on mature tumor vasculature. Overall, 
total vasculature in tumors was reduced by 34%. Angiogen-
esis, or the formation of new vessels from existing vessels, 
is imperative for tumor growth and progression as neoplastic 
cells require nutrient delivery and waste removal. As a result 
of hypoxia and other factors in the tumor microenvironment, 
Figure 2 Tumor area in LHBeTATAg retinal tumors. The uninvolved retina appears 
normal, and no signs of retinal toxicity are evident. A) saline treated, B) anecortave 
acetate (AA) treated, C) 2-deoxyglucose (2-Dg) treated, D) 2-Dg 1 day post-
AA, and E) 2-DG 1 week post-AA. There was a significant reduction in tumor 
burden in the group treated with 2-Dg 1 day post-AA treatment in comparison 
with saline (61% reduction) as well as 2-DG alone (23% reduction) (P , 0.001 and   
P , 0.05, respectively). Original magnifications, ×40 for each group; representative 
H&e images.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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angiogenesis is stimulated, forming a haphazard network of 
new vessels that require stabilization by cytokines and growth 
factors, such as vascular endothelial growth factor. New ves-
sels consist of proliferating ECs, while mature vessels are 
supported by pericytes that provide necessary stabilization. 
ECs have been shown to rely on glycolysis for metabolism 
even under aerobic conditions.38–40 It has been hypothesized 
that proliferating cells may utilize glycolysis as an adaptation 
to oxidative stress secondary to oxygen free radicals.39,40 With 
a greater reliance on glycolysis for endothelial proliferation, 
2-DG as a glycolytic inhibitor may target ECs, effectively 
serving as an antiangiogenic agent.
The use of glycolytic inhibitors is a promising alternative 
for advanced disease. More importantly, the current study   
provides additional support to the mechanistic effect of 2-DG 
on angiogenesis. Because retinoblastoma tumors promote 
angiogenesis and are highly dependent on their vascular 
supply, a dual mechanistic effect of 2-DG targeting both the 
slowly proliferating hypoxic cells as well as the proliferating 
ECs is demonstrated.
Antiangiogenic agents, such as AA, inhibit vascular 
growth, effectively rendering a tumor without sufficient blood 
supply, leading to hypoxia and cell death. Prior studies have 
shown the efficacy of antiangiogenic agents in retinoblastoma 
tumor control in the LHBETATAG animal model.26 As tumors 
undergo proliferation, an ‘angiogenic switch’ occurs, where 
the tumor must stimulate angiogenesis to support further 
development. As tumors become more advanced, these neove-
ssels are remodeled and transformed into mature vessels. The 
ECs of new vessels rely on growth factors produced by gelati-
nase degradation of the extracellular matrix to support growth 
and development, while mature vessels rely on pericytes for 
support. Recently, we have shown that AA affects gelatinase 
activity, leading to a decrease in MMP-2 and MMP-9.41 Prior 
studies have correlated AA treatment with increased levels of 
plasminogen activator inhibitor 1, effectively impeding uPA 
activity.42,43 As a result, the dynamic tumor microenvironment 
consisting of a heterogeneous network of blood vessels can 
be targeted by angiogenic inhibitors. However, further strate-
gies to modulate or target the formation of mature vessels are 
needed to potentially maximize tumor control.
The results of our study emphasize a key concept regard-
ing adjuvant treatments and their effectiveness in tumor 
control, specifically, optimized timing. We have shown in 
prior studies that when AA is combined with chemothera-
peutic agents, the administration of AA after completion 
of the chemotherapy cycle yielded more effective tumor 
control than treatment during the cycle.26 It is hypothesized 
that angiogenic inhibitors alter blood flow through vessels, 
potentially reducing the delivery of chemotherapeutic agents 
to the tumor. Additionally, we have shown that when 2-DG 
is combined with carboplatin, tumor control is enhanced 
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when 2-DG is given prior to chemotherapy.25 Further, with 
the current study, timing of 2-DG following AA treatment led 
to significant differences in advanced tumor control. AA has 
been shown to significantly reduce total vessel density in 
tumors, primarily immature neovessels, as well as increase 
hypoxia in tumors by 28% and 17% 1 day and 1 week post-
treatment, respectively.44 With reduction in blood vessels, 
there is a decrease in blood flow resulting in less delivery 
of oxygen and nutrients to highly metabolic neoplastic 
cells. The tumor microenvironment is altered, leading to a 
greater degree of hypoxia. With the increase in hypoxia fol-
lowing AA treatment, this is an optimal time for treatment 
with 2-DG which targets hypoxic cells. As a result, with 
optimally timed treatment using angiogenic and glycolytic 
inhibitors, advanced tumor control is enhanced more than 
with single-agent treatment. These studies emphasize that 
as adjuvant therapies are developed to target various aspects 
of the tumor microenvironment and associated genetic and 
molecular pathways, optimally timed delivery must be con-
sidered to not only enhance tumor control, but also to avoid 
antagonism between various treatment modalities.
Current therapy for retinoblastoma has improved survival 
and globe salvage, with chemotherapy and focal consolidation 
providing tumor control in 100% of tumors without seeding, to 
47%–83% in more advanced tumors with diffuse retinal and 
vitreous seeds.6,7 Despite treatment success, current chemo-
therapy exposes children to highly toxic medications with severe 
side effects. Additionally, advanced disease responds poorly to 
treatment, often necessitating enucleation for disease control. 
Adjuvant therapies, such as glycolytic inhibitors, angiogenic 
inhibitors, and agents that target molecular and genetic pathways 
involved in tumor proliferation could potentially be combined 
with current treatment regimens. The current study shows that 
tumor control can be achieved with combination therapy without 
the need for chemotherapy. Adjuvant therapies may eliminate the 
need for chemotherapy or allow reduced doses or cycles of toxic 
agents. Finally, combined treatment may provide enhanced con-
trol of advanced tumors that previously were resistant to therapy. 
Although 2-DG was administered systemically through intrap-
eritoneal injections, we are not advocating systemic delivery, 
secondary to potential effects on organ and vascular development. 
Rather, we have shown in prior studies that 2-DG and AA can 
be effectively delivered locally through subconjunctival injec-
tions. Additionally, with new protocols utilizing supraselective 
ophthalmic artery cannulation, adjuvant therapies may potentially 
be delivered focally by selective intra-arterial delivery.
From a recent interview with Dr Watson, a cofounder of 
the DNA double helix, he had this to say about the future of 
cancer treatment: ‘there are often many types of cancer-causing 
genetic “drivers” within single cancer cells … given the inherent 
genetic instability of most cancer cells, the use of drugs acting 
against single drivers would all too soon lead to the emergence 
of genetic variants driven by increasingly destructive second, 
if not third, drivers. Most anticancer drugs, then, will probably 
never reach their full potential unless they are given in combi-
nation with other drugs developed against second or even third 
drivers’.45 We feel that the future of retinoblastoma treatment 
echoes these sentiments, as we continue to show that adjuvant 
therapies that target components of the tumor microenviron-
ment can enhance tumor control and potentially decrease the 
reliance on toxic chemotherapeutic agents.
In the present study, we have characterized the effect 
of the combination treatment with 2-DG and AA on tumor 
Figure 4 Post-treatment hypoxia in LHBeTATAg retinal tumors. A) saline treated, 
B) anecortave acetate (AA) treated, C) 2-deoxyglucose (2-Dg) treated, D) 2-Dg 
1 day post-AA, and E) 2-DG 1 week post-AA. There is a significant decrease in the 
levels of hypoxia in eyes treated with 2-Dg alone as well as combination treatment 
(AA + 2-Dg) compared with the saline controls (P , 0.001, for both). representative 
composite images of pimonidazole (green)-stained and DAPi (blue, nuclear stain)-
stained ocular sections of LHBeTATAg mice treated with saline, AA, 2-Dg, 2-Dg 
1 day post-AA injection, or 2-Dg 1 week post-AA injection at ×200 magnification. 
Significant areas of hypoxia can be seen in the A) saline-treated group and the 
B) AA-treated group.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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growth, hypoxia, angiogenesis, and blood vessel matura-
tion in LHBETATAG retinal tumors. We have demonstrated 
that advanced tumor control is enhanced with combination 
therapy utilizing glycolytic and angiogenic inhibitors com-
pared to single agents alone. The effects were significantly 
influenced by the temporal relationship of therapies, thus 
emphasizing the importance of optimally timed treatments. 
The current findings suggest that angiogenic and glycolytic 
inhibitors can be combined with a synergistic effect on 
tumor control. We also demonstrated the dual mechanistic 
action of 2-DG by targeting hypoxic cells as well as ECs, 
effectively reducing angiogenesis. With a greater under-
standing of the mechanism of adjuvant therapies such as 
glycolytic inhibitors and angiogenic inhibitors, treatments 
may be effectively combined with or without current che-
motherapeutic agents. As a result, this combination may 
have potential value as adjuvant therapy for children with 
retinoblastomas.
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